Phaseline

Companies › Geropharm

Geropharm: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GP40141
Thrombopoietin receptor agonist
THPOPhase 3Drug EffectMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06497036GP40141Phase 3Drug EffectOtherMar 2028

Targets

THPO (1)

Companies with the same targets

MIBIO PTE. Sichuan Clover Biopharmaceuticals Chongqing Peg-Bio Biopharm

Companies built like this

Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma Vertanical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.